Saqqur Maher, Molina Carlos A, Salam Abdul, Siddiqui Muzaffar, Ribo Marc, Uchino Ken, Calleja Sergio, Garami Zsolt, Khan Khaurshid, Akhtar Naveed, O'Rourke Finton, Shuaib Ashfaq, Demchuk Andrew M, Alexandrov Andrei V
University of Alberta, Department of Medicine, Division of Neurology, 2 E3 Walter Mckenzie Center, 8440 112 Ave, Edmonton, Alberta T6G 2B7, Canada.
Stroke. 2007 Jan;38(1):69-74. doi: 10.1161/01.STR.0000251800.01964.f6. Epub 2006 Nov 30.
Patients may experience clinical deterioration (CD) after treatment with intravenous recombinant tissue plasminogen activator (rt-PA). We evaluated the ability of flow findings on transcranial Doppler to predict CD and outcomes on modified Rankin Scale.
Patients with acute stroke received intravenous rt-PA within 3 hours of symptom onset at four academic centers. CD was defined as an increase in the National Institutes of Health Stroke Scale (NIHSS) score by 4 points or more within 24 hours. Poor long-term outcome was defined by modified Rankin Scale > or =2 at 3 months. Transcranial Doppler findings were interpreted using the Thrombolysis in Brain Ischemia flow grading system as persistent arterial occlusion, reocclusion, or complete recanalization. Multiple regression analysis was used to identify transcranial Doppler flow as a predictor for CD after controlling for age, sex, baseline NIHSS, hypertension, and glucose.
A total of 374 patients received intravenous rt-PA at 142+/-60 minutes (median pretreatment NIHSS score 16 points). At the end of intravenous rt-PA infusion, transcranial Doppler showed persistent arterial occlusion in 219 patients (59%), arterial reocclusion in 54 patients (14%), and complete recanalization in 101 patients (27%). CD occurred in 44 patients: 36 had persistent arterial occlusion or reocclusion (82%), 13 symptomatic intracerebral hemorrhage (29%), and both persistent occlusion/reocclusion and symptomatic intracerebral hemorrhage in 10 patients (23%). After adjustment, patient risk for CD with persistent occlusion was OR 1.7 (95% CI: 0.7 to 4) and with arterial reocclusion 4.9 (95% CI: 1.7 to 13) (P=0.002). Patient risk for poor long-term outcomes with persistent occlusion, partial recanalization, or reocclusion was OR 5.2 (95% CI: 2.7 to 9, P=0.001).
Inability to achieve or sustain vessel patency at the end of rt-PA infusion correlates with the likelihood of clinical deterioration and poor long-term outcome. Early arterial reocclusion on transcranial Doppler is highly predictive of CD and poor outcome.
静脉注射重组组织型纤溶酶原激活剂(rt-PA)治疗后,患者可能会出现临床病情恶化(CD)。我们评估了经颅多普勒血流检查结果预测CD以及改良Rankin量表结局的能力。
四个学术中心的急性卒中患者在症状发作3小时内接受静脉rt-PA治疗。CD定义为美国国立卫生研究院卒中量表(NIHSS)评分在24小时内增加4分或更多。3个月时改良Rankin量表>或=2定义为长期预后不良。经颅多普勒检查结果采用脑缺血溶栓血流分级系统解释为持续性动脉闭塞、再闭塞或完全再通。在控制年龄、性别、基线NIHSS、高血压和血糖后,采用多元回归分析确定经颅多普勒血流作为CD的预测指标。
共有374例患者在142±60分钟时接受静脉rt-PA治疗(治疗前NIHSS评分中位数为16分)。静脉rt-PA输注结束时,经颅多普勒显示219例患者(59%)存在持续性动脉闭塞,54例患者(14%)存在动脉再闭塞,101例患者(27%)完全再通。44例患者出现CD:36例存在持续性动脉闭塞或再闭塞(82%),13例有症状性脑出血(29%),10例患者同时存在持续性闭塞/再闭塞和症状性脑出血(23%)。调整后,持续性闭塞患者发生CD的风险比值比(OR)为1.7(95%置信区间:0.7至4),动脉再闭塞患者为4.9(95%置信区间:1.7至13)(P=0.002)。持续性闭塞、部分再通或再闭塞患者长期预后不良的风险OR为5.2(95%置信区间:2.7至9,P=0.001)。
rt-PA输注结束时无法实现或维持血管通畅与临床病情恶化及长期预后不良的可能性相关。经颅多普勒检查发现早期动脉再闭塞对CD和不良结局具有高度预测性。